Myhibbin (mycophenolate mofetil) is a ready-to-use liquid suspension that's approved for people ages 3 months and older. It helps prevent the body from rejecting a kidney, heart, or liver transplant. Myhibbin (mycophenolate mofetil) is a type of immunosuppressant medication called an antiproliferative agent; it works by weakening your immune system. Myhibbin (mycophenolate mofetil) is taken twice daily on an empty stomach. This medication has many possible side effects, including diarrhea, nausea, and changes in blood pressure.
Myhibbin (mycophenolate mofetil) is a type of immunosuppressant called an antiproliferative agent. It weakens your immune system by blocking your body from making certain immune system cells. This helps prevent your body from rejecting a transplanted organ.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Note: These side effects were reported by heart transplant recipients who took mycophenolate mofetil with other immunosuppressants. Side effects will depend on your dose, the type of transplant you receive, and your other immunosuppressants.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Both Myhibbin and Cellcept contain the same active ingredient (mycophenolate mofetil). They both work to prevent kidney, heart, or liver transplant rejection when they're taken with other anti-rejection medications. Cellcept is available as large capsules or tablets, as an infusion given in the vein in healthcare settings, and as a liquid suspension that your pharmacist has to prepare for you. Myhibbin is different in that it's a ready-to-use suspension that doesn't require mixing before use. Ask your transplant specialist about which medication is appropriate for you.
The manufacturer stated that Myhibbin (mycophenolate mofetil) should be available in pharmacies in the U.S. sometime during the spring of 2024. Ask your pharmacy if this medication is available or ask them to order it for you if you're prescribed Myhibbin (mycophenolate mofetil).
You should take Myhibbin (mycophenolate mofetil) on an empty stomach because taking it with food can lessen the amount of the medication that gets absorbed into your blood. This might put you at risk for transplant rejection because the medication might not work as well. It's possible that your prescriber might eventually let you start taking Myhibbin (mycophenolate mofetil) with food when your condition becomes stable (e.g., after you've been taking the same dose for a long time). It's important to be consistent and always take Myhibbin (mycophenolate mofetil) with food if your transplant team says that you can. This helps keep the medication levels in your body consistent (steady).
Yes. Myhibbin (mycophenolate mofetil) doesn't appear to have an interaction with coffee (or caffeine). Even though there probably isn't an interaction with coffee, you shouldn't mix Myhibbin (mycophenolate mofetil) with coffee or any other liquids before you take your dose of the medication.
The Myhibbin (mycophenolate mofetil) suspension has raspberry flavoring added to it.
No, you don't need to refrigerate Myhibbin (mycophenolate mofetil). You can keep this medication at room temperature.
Take Myhibbin (mycophenolate mofetil) and your other anti-rejection medications for as long as your transplant specialist instructs you to. This helps keep your body from rejecting the transplanted organ. Usually, your transplant care team will tell you to stop taking Myhibbin (mycophenolate mofetil) only if you're having a side effect that's too bothersome for you or if you're having a very serious side effect. You might also transition from Myhibbin (mycophenolate mofetil) to a different medication if your prescriber decides to switch your treatment.
Myhibbin (mycophenolate mofetil) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Don't take Myhibbin (mycophenolate mofetil) if you're pregnant and if there are safer treatment options available. This medication can raise the risk for miscarriage (pregnancy loss) during the first trimester and birth defects if it's taken during pregnancy.
If you can become pregnant, you'll need to take a pregnancy test before you start Myhibbin (mycophenolate mofetil) and also periodically during treatment. Also use effective birth control during treatment if you're sexually active and you or your partner can become pregnant. Continue using birth control for at least 6 weeks (for females) and for at least 3 months (for males) after you take your last dose. Note that this medication can lower how well levonorgestrel-containing birth control works. Discuss with your transplant team about other treatment options if you're thinking of becoming pregnant.
People who take immunosuppressants like Myhibbin (mycophenolate mofetil) for a long time might be at higher risk for cancer. These cancers can include lymphomas and skin cancer, among others. Your transplant specialist will check your risk of cancer during treatment. Speak with your transplant team if you're concerned about the risk for cancer with Myhibbin (mycophenolate mofetil).
To lower your risk for skin cancer specifically, wear protective clothing and use sunscreen when you go outside. Also avoid ultraviolet light (e.g., tanning beds). Make sure to check your skin for any unusual changes and tell your care team if you notice anything strange.
Myhibbin (mycophenolate mofetil) can affect your body's ability to fight off infections. This can raise your risk for serious and sometimes life-threatening infections, including those caused by bacteria, fungi, or viruses. For example, some serious viral infections have included progressive multifocal leukoencephalopathy (PML) and COVID-19, among others. In some cases, infections can happen when an inactive germ in your body, like the bacteria that cause tuberculosis (TB) or the hepatitis virus, reactivates and makes you sick again.
Your transplant care team will examine you routinely for infections before you start Myhibbin (mycophenolate mofetil) and during treatment. Let your transplant team know as soon as possible if you notice any signs of infection like fever, chills, body aches, cough, or pain when urinating.
Some people who take Myhibbin (mycophenolate mofetil) can have lower numbers of red blood cells (RBCs), white blood cells (WBCs), and platelets in the body. Low RBCs can put you at risk for anemia, low WBCs for infections, and low platelets for bleeding. Your transplant team will order blood draws during treatment to check your blood cell counts.
Let your transplant team know if you have possible symptoms of anemia, such as tiredness, headache, pale skin, fast heart rate, and trouble breathing. Also contact your care team if you notice you have small, flat red spots under the skin or easy bleeding or bruising. In addition, tell your transplant specialist right away if you have symptoms of an infection, like fever, chills, tiredness, cough, body aches, and runny nose.
Some people who took Myhibbin (mycophenolate mofetil) have had serious stomach problems, including bleeding and ulcers (sores). These stomach problems can be dangerous and might require treatment right away. Get medical help right away if you're feeling faint, vomiting blood, have bloody or dark stools, or have severe stomach pain or discomfort that doesn't go away while you're taking Myhibbin (mycophenolate mofetil). These can be signs of a bleed in the digestive tract.
Avoid taking Myhibbin (mycophenolate mofetil) if you have a genetic condition called hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. This medication can worsen your symptoms, including gout, kidney stones, other kidney problems, or even kidney failure.
Myhibbin (mycophenolate mofetil) weakens the immune system to lower inflammation to help prevent organ rejection. But very rarely, some people have had symptoms of inflammation in the body during treatment. Symptoms can include fever, joint or muscle pain, and changes in certain lab results. These symptoms can happen within weeks to months of starting Myhibbin (mycophenolate mofetil) or after dose changes.
Your transplant team will check for signs and symptoms of inflammation during treatment with Myhibbin (mycophenolate mofetil). Tell your transplant team right away if you have any fever, joint pain, or muscle pain while you're taking this medication.
Make sure you know how Myhibbin (mycophenolate mofetil) affects you before driving a car or doing activities that require your concentration. Myhibbin (mycophenolate mofetil) can cause sleepiness, dizziness, and confusion. These side effects can lower your ability to think, react, and focus. You're at greater risk for these side effects if you're also taking other medications that can cause drowsiness, such as benzodiazepines and muscle relaxants. Myhibbin (mycophenolate mofetil) can also cause tremors (shakiness), which can make driving harder to do safely. Talk to your care team if you have these side effects while you're taking Myhibbin (mycophenolate mofetil) and if they're not getting better with time.
| Dosage | Quantity | Price as low as | Price per unit |
|---|---|---|---|
| 175ml of 200mg/ml | 1 bottle | $738.73 | $738.73 |
Adults
Children ages 3 months and older: The prescriber will calculate the dose based on your child's body size (height and weight). They'll tell you how much your child should take. Typically, Myhibbin (mycophenolate mofetil) is taken by mouth twice a day.
Your prescriber will adjust your dose based on how well the medication is working for you and whether you're having side effects. For people with a kidney transplant, the prescriber will adjust the dose depending on kidney function.
Contraindications are specific health conditions or situations in which a person should not take a medication due to safety concerns. If you have any of the following conditions or if any of the following apply to you, let your healthcare provider know because Myhibbin (mycophenolate mofetil) will not be safe for you to take.